SME info day - navigating EMA support: From development to market authorisation, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 6 November 2026, 09:15 (CET) to 6 November 2026, 15:30 (CET)

Human medicines European public assessment report (EPAR): Ozurdex, dexamethasone, Date of authorisation: 26/07/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Comirnaty, COVID-19 mRNA vaccine, Date of authorisation: 21/12/2020, Revision: 62, Status: Authorised

Emergency Task Force (ETF) recommendations

ETF recommends updating COVID-19 vaccines to target XFG variant

EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027

Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline

List of centrally authorised products with safety-related changes to the product information

Scientific advice for high-risk medical devices